Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25342466 | 0.81 | VRK1 (0.31) | — | |
| SCHEMBL4022386 | 0.72 | TDO2 (0.43) | LRRK2ALOX5APNOS3NOS2MAP4K4 | |
| SCHEMBL16679603 | 0.71 | NOS3 (0.46) | HTTKMT2AALOX5APFYNNOS3 | |
| SCHEMBL15750831 | 0.71 | NNMT (0.45) | HTTKMT2AFYNNOS3NOS1 | |
| SCHEMBL17629300 | 0.71 | NPC1 (0.32) | — | |
| SCHEMBL16679602 | 0.69 | FYN (0.43) | HTTKMT2AALOX5APFYNMAP4K4 | |
| SCHEMBL8390535 | 0.69 | MAPT (0.48) | — | |
| SCHEMBL1978092 | 0.67 | SMN1; SMN2 (0.43) | HTTKMT2A | |
| SCHEMBL17785560 | 0.67 | KDR (0.39) | FYN | |
| SCHEMBL25344261 | 0.67 | CRHR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | HTT 4048/4885KMT2A 431/4885LRRK2 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.